HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $110 price target.
Stocks · News reference
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50
Citigroup analyst Eric Joseph initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $50.
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Wedbush Reiterates Outperform on Maze Therapeutics, Maintains $48 Price Target
Wedbush analyst Laura Chico reiterates Maze Therapeutics (NASDAQ:MAZE) with a Outperform and maintains $48 price target.